Studying hard-to-treat inflammatory bowel disease
Part of Digestive system, Immune system & allergy clinical trials.
This study looks at people with inflammatory bowel disease (IBD) that is hard to manage. Researchers want to understand how common it is, how it is treated, and what happens over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with Crohn's disease, ulcerative colitis, or indeterminate IBD.
- You have seen a digestive specialist (gastroenterologist) at least once since January 1, 2019.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with Crohn's disease that is hard to treat. It aims to understand the disease better and see how well current treatments work.
This study looks at how well a treat-to-target approach works for people with Crohn's disease or ulcerative colitis in everyday medical care. By reviewing your medical history over the past 2 years, researchers hope to learn how to better manage these conditions and prevent long-term damage.
This study looks at what factors help predict how inflammatory bowel disease (IBD) may progress over time. You may be able to join if you are an adult with IBD and fit one of the study groups based on whether you have used TNF-blocking medicines before.
This trial studies treatment approaches for inflammatory bowel disease (IBD) in people who are newly diagnosed. It may help researchers find better care by learning how well the study treatment works early in the disease.
This trial looks at how to diagnose Inflammatory Bowel Disease (IBD) in people who have just been diagnosed. It may help find better ways to detect and manage the condition.
This study is gathering information from people with active Crohn's disease or ulcerative colitis, and from people without IBD. Researchers will look at samples from the colon to learn more about these conditions.
Hear when a new Assessment of the Criteria and Risk Factors for DTT-IBD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.